Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 31Carcinoma, Hepatocellular 30Neoplasms 19Carcinoma, Renal Cell 16Melanoma 10Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Endometrial Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Lymphoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma 3Biliary Tract Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Osteosarcoma 2Lung Neoplasms 2Kidney Neoplasms 2Glioma 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

peginterferon alfa-2a 1menatetrenone 1lenvatinib 1human papillomavirus vaccine, L1 type 16, 18 1Tenofovir 1Sorafenib 1PHY 906 1Engerix-B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hepatitis B × lenvatinib × Clear all
NCT05195294 2025-03-10

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Lion TCR Pte. Ltd.

Phase 2 Not yet recruiting
55 enrolled
Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡